Additionally, the recent clinical success of KRAS G12C inhibition in NSCLC represents a triumph towards a driver mutation that is frequent yet has been historically difficult to target, showing us the parallel evolution of technology in drug development alongside clinical therapy. Here, KRAS is linked to non-small cell lung carcinoma.